Daiichi Sankyo
Whoa! How did you get here? This company profile is not meant to be publicly available. Research on this company is incomplete, and the overall rating has been disabled, but while you are here feel free to have a look at the info we do have.
OVERALL |
|
Owned |
JPN |
Rating |
N/A |
Pharmaceuticals
Daiichi Sankyo Company Ltd | JPN | website |
Company Assessment
PRAISE | CRITICISM | INFORMATION | ||
Daiichi Sankyo Company Ltd | ||||
In 2023, the Carbon Disclosure Project (CDP) asked companies to provide data about their efforts to reduce greenhouse gas emissions and mitigate climate change risk. Responding companies are scored across four key areas: disclosure; awareness; management; and leadership. This company received a CDP Climate Change score of A.
Source: CDP (2023)
In 2023, the Carbon Disclosure Project (CDP) asked companies to provide data about their efforts to manage and govern freshwater resources. Responding companies are scored on six key metrics: transparency; governance & strategy; measuring & monitoring; risk assessment; targets & goals; and value chain engagement. This company received a CDP Water Security score of B-.
Source: CDP (2023)
This company received an S&P Global ESG Score of 79/100 in the Pharmaceuticals category of the S&P Global Corporate Sustainability Assessment, an annual evaluation of companies' sustainability practices (last updated 16 Dec 2022). The rankings are based on an analysis of corporate economic, environmental and social performance, assessing issues such as corporate governance, risk management, environmental reporting, climate strategy, human rights and labour practices.
Source: S&P Global (2022) |
This company received the fourth lowest score in the Access to Medicine Index 2022, a ranking of the world's 20 largest pharmaceutical companies on their efforts to increase access to medicine in developing countries. The ranking is based on their scores in each Technical Area, with Product Delivery weighted most highly, followed by R&D and Governance of Access.
Source: Access to Medicine Foundation (2022)
The 2022 Nature Benchmark ranks 400 companies across eight industries on their efforts to protect our environment and its biodiversity. The companies were assessed using three measurement areas: governance and strategy; social inclusion and community impact; and ecosystems and biodiversity. This company ranked #143/400, with a total score of 18.3/100.
Source: World Benchmarking Alliance (2022) |
As listed on the We Mean Business website, this company has committed to the following climate action initiatives: adopt a science-based emissions reduction target; commit to 100% renewable power.
Source: We Mean Business (2021) |
Company Details
Type | Public company |
Founded | 2005 |
Contact Details
Address | Tokyo, Japan |
Website | www.daiichisankyo.com |